Tuesday, September 27, 2022 8:06:53 AM
September 27, 2022 08:00 ET | Source: Nemaura Medical, Inc
CHICAGO and LOUGHBOROUGH, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces that it has entered into a preliminary agreement with EVERSANA®, a pioneer of next-generation commercial services to the global life sciences industry.
The agreement covers the U.S. and all global sales and marketing of Nemaura’s Diabetes Management Solution, BEATdiabetes. The BEATdiabetes program is based on Nemaura’s noninvasive glucose monitoring solution, proBEAT. Nemaura and EVERSANA will work together to develop the optimal launch strategy for large-scale adoption of the diabetes management program, including franchising and direct sales to self-insured corporate clients and healthcare insurers.
In early pilot trials conducted over the last 12 months, the BEATdiabetes program yielded overall positive outcomes, demonstrating that sustainable, long-term weight loss and, therefore, improvement in the management of Type 2 diabetes is achievable. Incumbents in the space have also demonstrated clinically significant outcomes when such diabetes management programs are used in conjunction with continuous glucose monitors. Nemaura, however, has the advantage of its own proprietary noninvasive sensor technology which significantly reduces sensor costs, as the sensors are only worn a few days each month.
EVERSANA is widely regarded as the leader in digital therapeutic commercialization. Across the life sciences industry, the fully integrated commercialization provider works with more than 670 organizations, including innovative start-ups and established pharmaceutical companies.
Dr. Faz Chowdhury, Nemaura Medical’s Chief Executive Officer, stated, “We are excited to be working with EVERSANA to bring our diabetes management solution to market. This is a culmination of several months of negotiations with EVERSANA following the encouraging outcome of the pilot studies. Diabetes management is an area of huge unmet need, and we anticipate that our solution will be very easy, simple to administer, and highly cost-effective, all elements supporting large-scale adoption.”
Jim Lang, Chief Executive Officer of EVERSANA, added, “Nemaura’s innovative programs and sensor technology potentially represent a major change in the way in which diabetes is addressed and how patients may be supported. We look forward to leveraging our full suite of commercialization services to support a successful U.S. launch.”
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing and commercialising noninvasive wearable diagnostic devices. The company is currently commercialising sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a noninvasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines noninvasive glucose data processed using artificial intelligence and a digital healthcare subscription service that has been launched in the U.S. as a general wellness product as part of its BEAT® diabetes program that is currently undergoing pilot studies.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
About EVERSANA™
EVERSANA™ is a leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners, and payers. The company serves more than 670 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter.
Media Contacts
Jules Abraham
CORE IR
+1 917-885-7378
EVERSANA
Matt Braun
Director, Corporate Communications
matt.braun@eversana.com
+1 414-434-4830
Recent NMRD News
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 04/19/2024 08:05:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2024 08:16:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:05:11 PM
- Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET • GlobeNewswire Inc. • 01/22/2024 09:15:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/17/2024 10:17:04 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/17/2024 10:15:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 10:30:57 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 10:29:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 09:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 12:00:07 PM
- Important Update on Listing Status and Strategic Direction • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 01:00:08 PM
- Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision • GlobeNewswire Inc. • 12/13/2023 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/07/2023 03:46:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/21/2023 01:38:51 PM
- Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth • GlobeNewswire Inc. • 11/21/2023 01:30:00 PM
- Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs • GlobeNewswire Inc. • 11/14/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:15:26 PM
- Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 11/13/2023 09:14:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 08:05:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 08:10:28 PM
- Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs. • GlobeNewswire Inc. • 09/26/2023 01:50:00 PM
- Maxim Group LLC to Host the Virtual Tech Conference Series: Emerging Growth in A.I., on Tuesday, September 26th & Wednesday, September 27th at 8:00 A.M. ET. • GlobeNewswire Inc. • 09/22/2023 07:05:36 PM
- Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference • GlobeNewswire Inc. • 09/18/2023 01:15:00 PM
FEATURED Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM